Liferna Biotech

Executive Summary

Liferna Biotech is a privately held biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company is focused on developing first-in-class RNA-based therapeutics for autoimmune and fibrotic diseases, with an initial emphasis on systemic sclerosis (SSc). By leveraging proprietary delivery technologies and a precision medicine approach, Liferna aims to address significant unmet medical needs in diseases characterized by fibrosis and immune dysregulation. The company's platform has the potential to generate disease-modifying treatments that could alter the course of SSc, for which current therapies are largely symptomatic. As a private firm, Liferna has not disclosed its funding or valuation, but its roots in the Cambridge biotech ecosystem suggest access to talent and capital. The company remains in early development stages, with no publicly disclosed clinical trials or approved products, making it a high-risk, high-reward opportunity in the RNA therapeutics space.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead SSc Program40% success
• Q2 2026Preclinical Proof-of-Concept Data Presentation60% success
• Q3 2026Series A Financing Announcement50% success